Clinical Study
Evaluation of X-Chromosome Inactivation Patterns in Patients with Acute Myeloid Leukemia during Remission
Table 2
Features of the patients who were followed after remission.
| Patients number | Age | Diagnosis (FAB) |
Clonality | Duration of following (month) | Cytogenetics | Flow cytometry |
| 26 | 40 | M3 | Mono. | 8 | 46XX, t(15; 17) (q22; q21)/46, XX | Compatible with M3 | 28 | 20 | M3 | Mono. | 12 | 46XX, t(15; 17) (q22; q21)/46, XX | Compatible with M3 | 33 | 21 | M3 | Mono. | 6 | 46XX, t(15; 17) (q22; q21)]/46, XX | Compatible with M3 | 35 | 43 | M3 | Mono. | 6 | 46XX, t(15; 17) (q22; q21)/46, XX | Compatible with M3 | 36 | 45 | M3 | Mono. | 6 | 46XX, t(15; 17) (q22; q21)/46, XX | Compatible with M3 | 40 | 21 | M3 | Poly. | 7 | 46XX, t(15; 17) (q22; q21) | Compatible with M3 | 43 | 20 | M2 | Poly. | 5 | 46XX, t(15; 17) (q22; q21)/46, XX | Compatible with M2 | 45 | 34 | M2 | Mono. | 4 | N.A | N.A | 47 | 40 | M3 | Mono. | 6 | 46XX, t(8; 15; 17) (q24.10; q21)ort(8; 14)(q11; q32), t(15; 17) (q22; q21)/46, XX | Compatible with M3 | 48 | 20 | M3 | Poly. | 5 | 46XX, t(15; 17) (q22; q11–21)/46, XX | Compatible with M3 |
|
|